I’m in remission from small lymphocytic lymphoma and off treatment, savoring this break while learning to live with the ...

Dr. Erika Hamilton discusses the most notable breast cancer treatments currently in development, and how might they change care for patients in the future.

Monjuvi added to Rituxan and Revlimid extended progression-free survival from 14 to 22 months in follicular lymphoma, ...

A subtle ad about breast cancer self-checks led me to reflect on my own experience and the complex role of pharmaceutical companies in awareness.

In a candid interview with CURE, Terry Gillespie reflects on how her definition of survivorship has evolved from her lung ...

A real-world study showed a 49% response rate with Amtagvi in patients with advanced melanoma, supporting earlier use after immunotherapy.

Dr. Breelyn Wilky urged newly diagnosed GIST patients to seek support from peers and advocacy groups, and to consult experts, even if care stays local.

The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing ...

Dr. Nicholas James shares why it’s important to identify which patients with high-risk, non-metastatic prostate cancer will ...

I was diagnosed with breast cancer, then lung cancer 17 years later — and both ultimately led me to make meaningful, positive ...

Thirteen years after cervical cancer, I’ve found strength in healing, grief in silence, and hope in sharing the quiet truths ...

Five years after my lymphoma diagnosis, life looks normal on the outside; however, the fear of recurrence and the reality of ...